Current issues regarding tamoxifen and the genital tract

A review

Paniti Sukumvanich, Dineo Khabele, Gary L. Goldberg

Research output: Contribution to journalArticle

Abstract

In summary, tamoxifen remains the hormonal treatment of choice for the prevention and treatment of breast cancer. The primary significant risks of tamoxifen are the increased risks of thromboembolism and uterine cancers. There is an increased risk of endometrial cancer, with a small but significant increased risk of uterine sarcomas, specifically malignant mixed mullerian tumors. Therefore, abnormal bleeding in patients on tamoxifen should be evaluated and an endometrial biopsy obtained. If no tissue is obtained by endometrial biopsy, a D& C and hysteroscopy should be considered. Other effects on the genital tract, although not life threatening, are important as they may affect the patient's quality of life. These symptoms should be addressed during the patient's gynecological evaluation, since they can be treated without adversely impacting upon the patient's breast cancer risk and treatment.

Original languageEnglish (US)
Pages (from-to)85-94
Number of pages10
JournalWomen's Oncology Review
Volume4
Issue number2
DOIs
StatePublished - Jun 2004

Fingerprint

Tamoxifen
Malignant Mixed Tumor
Breast Neoplasms
Biopsy
Hysteroscopy
Uterine Neoplasms
Thromboembolism
Endometrial Neoplasms
Sarcoma
Therapeutics
Quality of Life
Hemorrhage

ASJC Scopus subject areas

  • Oncology

Cite this

Current issues regarding tamoxifen and the genital tract : A review. / Sukumvanich, Paniti; Khabele, Dineo; Goldberg, Gary L.

In: Women's Oncology Review, Vol. 4, No. 2, 06.2004, p. 85-94.

Research output: Contribution to journalArticle

Sukumvanich, Paniti ; Khabele, Dineo ; Goldberg, Gary L. / Current issues regarding tamoxifen and the genital tract : A review. In: Women's Oncology Review. 2004 ; Vol. 4, No. 2. pp. 85-94.
@article{1e72787b8bc44fd4ab7b5d7a595c6fe4,
title = "Current issues regarding tamoxifen and the genital tract: A review",
abstract = "In summary, tamoxifen remains the hormonal treatment of choice for the prevention and treatment of breast cancer. The primary significant risks of tamoxifen are the increased risks of thromboembolism and uterine cancers. There is an increased risk of endometrial cancer, with a small but significant increased risk of uterine sarcomas, specifically malignant mixed mullerian tumors. Therefore, abnormal bleeding in patients on tamoxifen should be evaluated and an endometrial biopsy obtained. If no tissue is obtained by endometrial biopsy, a D& C and hysteroscopy should be considered. Other effects on the genital tract, although not life threatening, are important as they may affect the patient's quality of life. These symptoms should be addressed during the patient's gynecological evaluation, since they can be treated without adversely impacting upon the patient's breast cancer risk and treatment.",
author = "Paniti Sukumvanich and Dineo Khabele and Goldberg, {Gary L.}",
year = "2004",
month = "6",
doi = "10.1080/14733400410001726025",
language = "English (US)",
volume = "4",
pages = "85--94",
journal = "Women's Oncology Review",
issn = "1473-3404",
publisher = "Parthenon Publishing Group",
number = "2",

}

TY - JOUR

T1 - Current issues regarding tamoxifen and the genital tract

T2 - A review

AU - Sukumvanich, Paniti

AU - Khabele, Dineo

AU - Goldberg, Gary L.

PY - 2004/6

Y1 - 2004/6

N2 - In summary, tamoxifen remains the hormonal treatment of choice for the prevention and treatment of breast cancer. The primary significant risks of tamoxifen are the increased risks of thromboembolism and uterine cancers. There is an increased risk of endometrial cancer, with a small but significant increased risk of uterine sarcomas, specifically malignant mixed mullerian tumors. Therefore, abnormal bleeding in patients on tamoxifen should be evaluated and an endometrial biopsy obtained. If no tissue is obtained by endometrial biopsy, a D& C and hysteroscopy should be considered. Other effects on the genital tract, although not life threatening, are important as they may affect the patient's quality of life. These symptoms should be addressed during the patient's gynecological evaluation, since they can be treated without adversely impacting upon the patient's breast cancer risk and treatment.

AB - In summary, tamoxifen remains the hormonal treatment of choice for the prevention and treatment of breast cancer. The primary significant risks of tamoxifen are the increased risks of thromboembolism and uterine cancers. There is an increased risk of endometrial cancer, with a small but significant increased risk of uterine sarcomas, specifically malignant mixed mullerian tumors. Therefore, abnormal bleeding in patients on tamoxifen should be evaluated and an endometrial biopsy obtained. If no tissue is obtained by endometrial biopsy, a D& C and hysteroscopy should be considered. Other effects on the genital tract, although not life threatening, are important as they may affect the patient's quality of life. These symptoms should be addressed during the patient's gynecological evaluation, since they can be treated without adversely impacting upon the patient's breast cancer risk and treatment.

UR - http://www.scopus.com/inward/record.url?scp=4644346839&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4644346839&partnerID=8YFLogxK

U2 - 10.1080/14733400410001726025

DO - 10.1080/14733400410001726025

M3 - Article

VL - 4

SP - 85

EP - 94

JO - Women's Oncology Review

JF - Women's Oncology Review

SN - 1473-3404

IS - 2

ER -